Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma
18h agoen
From the article
Conditions : Gastric Cancer; Gastroesophageal Junction (GEJ) Adenocarcinoma; Becotatug Vedotin; Pucotenlimab Interventions : Drug: Becotatug Vedotin (MRG003); Drug: Pucotenlimab Sponsors : West China Second University Hospital Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial
doi.org·6d ago
Real-World EV Plus Pembro Success Seen in Urothelial Cancer
Medscape·1d ago
GE HealthCare and Mayo Clinic launch theranostics study to personalize prostate cancer treatment
GE HealthCare and Mayo Clinic have launched the MI-BET research collaboration, a theranostics study aimed at developing a more personalized
mayocl.in·1d ago
Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma
This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in
mdsc.pe·19d agoGlaxoSmithKline submits European marketing authorisation application for Pazopanib in advanced kidney cancer
GSK·17y ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.